Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma

References

• Landgren O, Waxman AJ. Multiple myeloma precursor disease. JAMA. 2010;304:2397–2404.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–1127.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582–2590.
   PubMed Web of Science ®Google Scholar
• Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324:73–76.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Annu Rev Immunol. 1988;6:485–512.
   PubMed Web of Science ®Google Scholar
• Tanabe O, Kawano M, Tanaka H, et al. BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am J Hematol. 1989;31:258–262.
   PubMed Web of Science ®Google Scholar
• Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother. 2013;40:336–343.
   PubMed Web of Science ®Google Scholar
• Kawano MM, Mihara K, Huang N, et al. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood. 1995;85:487–494.
   PubMed Web of Science ®Google Scholar
• Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood. 1999;94:701–712.
   PubMed Web of Science ®Google Scholar
• Hunsucker SA, Magarotto V, Kuhn DJ, et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011;152:579–592.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res. 2007;13:6469–6478.
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517–526.
   PubMed Web of Science ®Google Scholar
• Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712–3720.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607–618.
   PubMed Web of Science ®Google Scholar
• Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58:573–581.
   PubMed Web of Science ®Google Scholar
• Tadamitsu K, Shizuo A, Tetsuya T. IL-6 receptor and mechanism of signal transduction. Int J Immunopharmacol. 1992;14:431–438.
   PubMed Web of Science ®Google Scholar
• Bloem AC, Lamme T, de Smet M, et al. Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines. Br J Haematol. 1998;100:166–175.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol. 2009;145:481–490.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;161:357–366.
   PubMed Web of Science ®Google Scholar
• Guo DJ, Han JS, Li Y-S, et al. In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma. Oncol Lett. 2012;4:311–318.
   PubMed Web of Science ®Google Scholar
• Bedewy AM, El-Maghraby SM. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients? Eur J Haematol. 2014;92:13–18.
   PubMed Web of Science ®Google Scholar
• Perez-Andres M, Almeida J, Martín-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19:449–455.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Fenton JA, Ashcroft J, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood. 2000;96:3880–3886.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Child JA, Anderson K, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812–817.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785–789.
   PubMed Web of Science ®Google Scholar
• Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586–2592.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson M, Paiva B, Stoolman L, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom. 2016;90:26–30.
   PubMed Web of Science ®Google Scholar
• Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014;38:371–376.
   PubMed Web of Science ®Google Scholar
• Jasper GA, Arun I, Venzon D, et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry. 2011;80:83–90.
   PubMedGoogle Scholar
• Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014;38:371–376.
   PubMed Web of Science ®Google Scholar
• Manasanch E, Salem DA, Yuan CM, et al. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leuk Lymph. 2014;38:371–376.
   Google Scholar
• Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90:31–39.
   PubMed Web of Science ®Google Scholar
• Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107:121–131.
   PubMed Web of Science ®Google Scholar
• Paiva B, Vidriales MB, Pérez JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica. 2009;94:1599–1602.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002;99:1853–1856.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431–438.
   PubMed Web of Science ®Google Scholar
• Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986–2010.
   PubMed Web of Science ®Google Scholar